-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$5.77477% Upside
CytomX Therapeutics, Inc. Frequently Asked Questions
-
What analysts cover CytomX Therapeutics, Inc.?
CytomX Therapeutics, Inc. has been rated by research analysts at BMO Capital, Piper Sandler, Wedbush, Jefferies in the past 90 days.